Google
Trusted Resources: News & Events
Latest announcements and gatherings
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta thalassemia
La Jolla Pharmaceutical company today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic human hepcidin) in patients with transfusion-dependent beta thalassemia who, despite chelation therapy, have cardiac iron levels above normal. A high level of cardiac iron puts patients at risk of cardiac complications such as heart failure and sudden death.
LJ401-BT01 is a pivotal, multinational, multicenter, randomized, controlled study that is designed to enroll approximately 100 patients across 9 countries, including the United States. Patients will be randomized 1:1 to receive either: (i) weekly subcutaneous injections of LJPC‑401, while continuing standard-of-care chelation therapy (LJPC‑401 treatment arm); or (ii) a continuation of standard-of-care chelation therapy only (observation arm).
+myBinderRelated Content
-
Gene therapy targets sickle-cell diseaseElliott Vichinsky estimates that at leas...
-
Sickle Cell Stories: Office of Minority Health, U.S. Department of Health and Human Serviceshttps://www.youtube.com/watch?v=HFojyaji...
-
Pediatric pain screening identifies youth at risk of chronic pain in sickle cell diseaseBackground: This study aimed to evaluat...
-
These patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
-
Today’s Faces of Sickle Cell Disease: Kirti DasuKirti Dasu was born in South East India ...
-
Newborn Blood Spot Screening for Galactosemia, Tyrosiemia Type I, Homocystinuria, Sickle Cell Anemia, Sickle Cell/Be...Existing evidence reviews on newborn blo...
-
1st Patients to Get CRISPR Gene-Editing Treatment Continue to ThriveThe last thing a lot of people want to d...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.